Innovent Biologics, Inc.

1801

KYG4818G1010

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-17 am EDT			5-day change	1st Jan Change
40.05 ^HKD	+0.63%		-3.26%	-6.32%

May. 07	Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	CI
Apr. 30	Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	CI

Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024

April 30, 2024 at 05:00 am EDT

Innovent Biologics, Inc. reported revenue results for the first quarter of 2024. for the quarter, the Company achieved a total product revenue exceeding RMB 1.7 billion, representing a robust year-over-year growth of over 60%.

Latest news about Innovent Biologics, Inc.

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	May. 06	CI
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	Apr. 30	CI
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer	Apr. 30	CI
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	Apr. 16	CI
Hutchmed endometrial cancer treatment application accepted for review	Apr. 02	AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	Apr. 02	MT
HSBC in special payout on Canada sale; Astra FDA win	Apr. 02	AN
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	Apr. 02	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 02	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	Apr. 02	CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	Mar. 20	MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	Mar. 06	CI
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	Mar. 05	MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	Mar. 04	CI
Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy	Feb. 26	MT
Innovent Biologics' Phase 3 Trial for Thyroid Eye Disease Treatment Meets Primary Endpoints	Feb. 19	MT
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	Feb. 19	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee	Feb. 09	CI
Innovent Biologics’ New Drug Application for Weight Management Drug Accepted by Chinese Regulator	Feb. 07	MT
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China	Feb. 07	CI
Innovent Biologics Posts 65% Revenue Growth in Q4 of 2023	Feb. 06	MT
Innovent Biologics, Inc. Reports Revenue Results for the Fourth Quarter of 2023	Feb. 06	CI
Innovent Biologics Names New CFO	Feb. 05	MT

Chart Innovent Biologics, Inc.

Duration

Period

More charts

Company Profile

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkinâs lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Sector

Pharmaceuticals

Calendar

2024-05-30 - American Society of Clinical Oncology Annual Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Innovent Biologics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.07 CNY

Average target price

51.07 CNY

Spread / Average Target

+37.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INNOVENT BIOLOGICS, INC.	-6.32%	8.35B
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B

Biopharmaceuticals